Wall Street Loves FIGS—Why Do Price Targets Predict Pullback?

Why It Matters

FIGS’ rapid price appreciation highlights the market’s optimism on post‑pandemic healthcare spending, yet the lofty valuation raises concerns about sustainability. Investors and analysts must weigh growth prospects against the risk of a correction.

Key Takeaways

• Revenue rose 33% to $200 million Q4 2025.
• International sales up 55%; core scrubwear 35% growth.
• Analysts raise targets, but P/E near 90 suggests overvaluation.
• Stock outperforms targets, trading above $17, double prior forecasts.

Pulse Analysis

FIGS entered the public markets in May 2021 amid a pandemic‑driven surge in demand for medical scrubs, debuting at $22 and quickly climbing to $50 per share. As COVID‑19 cases fell, the company’s growth stalled and the stock slumped below $8 within a year, lingering in single‑digit territory for several quarters. A decisive turnaround began in early 2025 when the brand leveraged its premium positioning and expanded internationally, lifting the share price from under $4 to a four‑year high above $17 by March 2024. The rebound reflects both operational improvements and renewed investor confidence in healthcare apparel.

The catalyst for the latest rally was FIGS’ Q4 2025 earnings, which posted a 33% revenue increase to $200 million and a record $630 million for the full year. Core scrubwear sales grew 35%, while international revenue surged 55%, and adjusted EBITDA margins beat targets by more than 200 basis points despite tariff pressures. Analysts responded with upgraded price targets ranging from $15 to $17, and several firms moved their recommendations to Strong Buy or Overweight. Nonetheless, the stock now trades at a price‑to‑earnings multiple near 90, dwarfing the sub‑12 multiple of peers such as Lululemon.

The stark contrast between bullish analyst sentiment and the lofty valuation suggests a potential correction ahead. While FIGS benefits from a growing healthcare workforce and a differentiated product line, the market may already be pricing in most of its near‑term growth, leaving limited upside. Investors should monitor the company’s ability to sustain margin expansion, navigate tariff headwinds, and execute its international expansion plan. A disciplined approach that balances the company’s impressive earnings momentum against its high multiple will be key to managing risk in a volatile tech‑wear sector.